Clinical trial NCT03358628: Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma
Official title: Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osterosarcoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteosarcoma
Keywords: Osteosarcoma
Patient-derived xenograft
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-11-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with high-grade osteosarcoma referred to, or being treated at Peking University People's Hostpital.

Brief summary: By obtaining clinical specimens from participants with high-grade bone and soft tissue sarcomas to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with individualized cancer treatment options

Detailed description: Patient-derived xenografts (PDX) are increasingly used as tools for drug development in pre-clinical settings, and have been shown to recapitulate the histology and behavior of the cancers from which they are derived. Although, they have been commonly used productively as pre-clinical disease models to study disease biology and drug response, they have not been used prospectively to inform clinical management. PDX have been employed to inform clinical decision-making in small studies, which have shown high concordance between individual PDX and patient responses to therapy. While encouraging, the role of this approach in bone and soft tissue sarcomas and in the context of genomic drug matching strategies remains undefined. This has created an opportunity to evaluate the utility of PDX as clinical predictors to direct the use of chemo- and targeted therapies in combination with comprehensive genomic and epigenetic analysis for patients with bone and soft tissue sarcomas.

Eligibility criteria: Inclusion Criteria:

1. Age \>18 years;
2. Diagnosis confirmed histologically and reviewed centrally;
3. Prior treatment (completed \>4 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide; metastatic relapsed and unresectable progressive disease (PD);
4. Eastern Cooperative Oncology Group performance status 0-1 with a life expectancy \>3 months;
5. Adequate renal, hepatic, and hemopoietic function;
6. Normal or controlled blood pressure;
7. Surgery and/or radiotherapy completion at least 1 month before enrollment.

Exclusion Criteria:

1. Central nervous system metastasis;
2. Have had other kinds of malignant tumors at the same time;
3. Cardiac insufficiency or arrhythmia;
4. Uncontrolled complications, such as diabetes mellitus and so on;
5. Coagulation disorders;
6. Urine protein≥ ++;
7. Pleural or peritoneal effusion that needs to be handled by surgical treatment;
8. Combined with other infections or wounds.

Primary outcomes:
measure: Measure of drug sensitive PDX to a panel of drugs as a predictor of clinical response in matched host
timeFrame: up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Peking University People's Hospital
name: Wei Guo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: